Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy. - Revach OY; Cicerchia AM; Shorer O; Petrova B; Anderson S; Park J; Chen L; Mehta A; Wright SJ; McNamee N; Tal-Mason A; Cattaneo G; et al. (BioRxiv : the preprint server for biology, 2024)